Scientists Are Building an Acne Vaccine That Targets the Bacteria Behind Breakouts

Acne affects roughly 85% of adolescents and tens of millions of adults, yet the standard toolkit has barely changed in decades: antibiotics that fuel resistance, retinoids that require monthly monitoring, and topical creams that work until they stop. A wave of new research suggests a more precise option may be on the horizon. Scientists at UC San Diego, Cedars-Sinai Medical Center, and UCLA have identified a bacterial enzyme responsible for driving skin inflammation, developed a vaccine to neutralize it, and reduced acne severity by half in a mouse model. Meanwhile, pharmaceutical giant Sanofi has moved an mRNA-based vaccine candidate into early-stage human trials.

This is still early, investigational science. No acne vaccine is approved, and meaningful human efficacy data is years away. But the mechanistic clarity of the UC San Diego work gives researchers a sharper target than anything the field has had before.

How HylA Enzyme Drives Acne Inflammation

The key insight from UC San Diego's research on the HylA enzyme is that not all Cutibacterium acnes (C. acnes) bacteria are equal. C. acnes is a naturally occurring resident of the skin microbiome, present on virtually everyone. The trouble lies in specific strains that produce a variant of the enzyme hyaluronidase called HylA.

HylA breaks down hyaluronic acid into large fragments that trigger a robust inflammatory immune response, the redness, swelling, and lesion formation that define acne. A second variant, HylB, breaks down the same molecule into smaller fragments that are actually anti-inflammatory. HylB is associated with healthy skin; HylA is associated with acne-prone skin. The two enzymes represent divergent evolutionary paths from the same bacterial species.

Using a mouse model built on synthetic sebum to more closely resemble the conditions of human skin, the team developed a vaccine that selectively targets and neutralizes HylA while leaving HylB intact. The result: acne severity fell by roughly half in treated mice. George Y. Liu, MD, PhD, described the goal as developing "a therapy that's much more tailored toward exactly what we know causes acne, rather than just generically blocking inflammation."

Why This Approach Could Transform Acne Treatment

For the millions of patients cycling through antibiotic prescriptions, the appeal is obvious. Current treatments address symptoms or suppress the immune system broadly; they rarely reach the underlying bacterial mechanism. Repeated antibiotic courses also accelerate resistance, a problem that extends well beyond dermatology.

There is also a mental health dimension that clinicians often underweight. Research on the psychological burden of acne documents elevated rates of depression, anxiety, poor self-image, and social isolation in patients, often independent of clinical severity. A condition that affects how a person moves through the world at 16 carries real stakes. A vaccine that reduces or prevents severe acne progression would matter enormously to that population.

Beyond direct inflammation control, the targeted approach aims to preserve the broader skin microbiome. Rather than wiping out C. acnes entirely, which could destabilize healthy bacterial communities, the vaccine would selectively disarm the strains causing harm. Researcher Irshad Hajam described the work as having "the potential to revolutionize acne therapies by offering more targeted treatments."

Sanofi's mRNA Vaccine Now in Phase 1/2 Human Trials

While the UC San Diego team refined its HylA-targeting approach in mice, Sanofi has taken a parallel mRNA-based strategy into humans. Sanofi's mRNA acne vaccine trial, registered as NCT07013747 and designed as a randomized, double-blind, placebo-controlled study, is enrolling adults aged 18 to 45 with mild to moderate or severe acne. Trial sites span the United States, Canada, Australia, and Singapore.

The vaccine candidate, ORI-A-ce001, uses mRNA technology similar in platform to the COVID-19 vaccines developed by Pfizer-BioNTech and Moderna. It is designed to boost the immune response against specific C. acnes strains and their inflammatory virulence factors. Sanofi completed a prior Phase 1 study (NCT05131373), though results from that earlier trial have not yet been published. The current Phase 1/2 study is assessing safety, tolerability, and immunogenicity; full efficacy data is not expected until 2029.

Open Questions About Microbiome Disruption and Vaccine Uptake

The scientific challenges are real. Acne is a multi-factorial condition: genetics, hormone levels, sebum production, and immune baseline all contribute. A vaccine that neutralizes one bacterial enzyme may reduce severity meaningfully for many patients while doing little for others whose acne is driven primarily by other factors.

There are also immunological engineering challenges specific to skin vaccine development. Researchers working on acne vaccine candidates have noted the difficulty of ensuring a new treatment does not disrupt the broader skin microbiome or trigger cross-reactivity with proteins beyond the intended target. Designing an immune response precise enough to neutralize HylA without inadvertently affecting HylB or unrelated skin proteins is a narrow target.

Beyond the biology, acne vaccine development faces practical hurdles, including potential vaccine hesitancy for a condition that is not life-threatening, and the regulatory expectation that benefits clearly outweigh risks for a quality-of-life indication. Standardized outcome measures for acne severity also remain inconsistent across trials, complicating future efficacy comparisons.

What Comes Next for HylA Research and Sanofi's Trial

The UC San Diego team's mouse data provides proof of concept for the HylA-neutralizing strategy, but the path to a human-ready product involves demonstrating that the immune response generated in mice translates to people, and that it holds up over the months-long timescales relevant to acne management. Researchers have also flagged additional bacterial virulence factors, including the Christie-Atkins-Munch-Peterson (CAMP) factor, as potential secondary targets that could be incorporated into future vaccine designs.

For Sanofi's trial, the primary readout will be safety and immune response, with Phase 1/2 results not expected before 2029. If those results are encouraging, a larger efficacy trial would follow before any regulatory submission. The optimistic scenario, a vaccine available to patients, is probably a decade away.

Still, the field is moving faster than it has in years. The combination of a mechanistically validated target in HylA, a platform technology in mRNA that has already proven scalable, and growing recognition of acne's psychological toll has focused serious scientific and commercial resources on a problem that medicine has long treated as cosmetic. That shift in framing may matter as much as any single clinical result.

Evidence rating

INVESTIGATIONAL — 67/100

This article summarizes preclinical mouse-model research and an ongoing early-stage Phase 1/2 human clinical trial (results not expected until 2029) with no published human efficacy data. The mechanistic work on HylA and HylB variants is specific and biologically detailed, but the human evidence base does not yet exist. No causal conclusions in humans can be drawn at this stage.

References

1. (2026). No more breakouts? A new acne vaccine could hold the key. – The Boston Globe. https://www.bostonglobe.com/2026/06/18/metro/acne-vaccine-treatment-breakouts/
2. Groundbreaking Research Paves the Way for Acne Vaccine – UC San Diego Today. health.ucsd.edu. https://health.ucsd.edu/news/releases/Pages/2023/12-05-groundbreaking-research-paves-the-way-for-acne-vaccine.aspx
3. Acne Vulgaris: The Psychosocial & Psychological Burden Of Illness. NIH. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195847/
4. A Study to Evaluate the Safety, Tolerability, and Immunogenicity of an mRNA-based Vaccine in Adults With Moderate to Severe Facial Acne Vulgaris. clinicaltrials.gov. https://clinicaltrials.gov/study/NCT06316297
5. Eyan Goh, Jean-Marc Chavatte, Raymond T. P. Lin, Lisa F. P. Ng, Laurent Rénia, Hazel H. Oon (2025). Vaccines in Dermatology—Present and Future: A Review. Vaccines. https://doi.org/10.3390/vaccines13020125
6. Could acne be prevented with a vaccine?. Nature. https://www.nature.com/articles/d41586-026-00624-9